Skip to content
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Menu
Home
About Us
Resources
Profiles Metrics
Authors Directory
Institutions Directory
Top Authors
Top Institutions
Top Sponsors
AI Digest
Contact Us
Publication Details
AFRICAN RESEARCH NEXUS
SHINING A SPOTLIGHT ON AFRICAN RESEARCH
Paromomycin for the treatment of visceral leishmaniasis in Sudan: A randomized, open-label, dose-finding study
PLoS Neglected Tropical Diseases, Volume 4, No. 10, Article e855, Year 2010
Notification
URL copied to clipboard!
Description
Background: A recent study has shown that treatment of visceral leishmaniasis (VL) with the standard dose of 15 mg/kg/day of paromomycin sulphate (PM) for 21 days was not efficacious in patients in Sudan. We therefore decided to test the efficacy of paramomycin for a longer treatment duration (15 mg/kg/day for 28 days) and at the higher dose of 20 mg/kg/day for 21 days. Methods: This randomized, open-label, dose-finding, phase II study assessed the two above high-dose PM treatment regimens. Patients with clinical features and positive bone-marrow aspirates for VL were enrolled. All patients received their assigned courses of PM intramuscularly and adverse events were monitored. Parasite clearance in bone-marrow aspirates was tested by microscopy at end of treatment (EOT, primary efficacy endpoint), 3 months (in patients who were not clinically well) and 6 months after EOT (secondary efficacy endpoint). Pharmacokinetic data were obtained from a subset of patients weighing over 30 kg. Findings: 42 patients (21 per group) aged between 4 and 60 years were enrolled. At EOT, 85% of patients (95% confidence interval [CI]: 63.7% to 97.0%) in the 20 mg/kg/day group and 90% of patients (95% CI: 69.6% to 98.8%) in the 15 mg/kg/day group had parasite clearance. Six months after treatment, efficacy was 80.0% (95% CI: 56.3% to 94.3%) and 81.0% (95% CI: 58.1% to 94.6%) in the 20 mg/kg/day and 15 mg/kg/day groups, respectively. There were no serious adverse events. Pharmacokinetic profiles suggested a difference between the two doses, although numbers of patients recruited were too few to make it significant (n = 3 and n = 6 in the 20 mg/kg/day and 15 mg/kg/day groups, respectively). Conclusion: Data suggest that both high dose regimens were more efficacious than the standard 15 mg/kg/day PM for 21 days and could be further evaluated in phase III studies in East Africa. © 2010 Musa et al.
Available Materials
https://efashare.b-cdn.net/share/pmc/articles/PMC2964291/bin/pntd.0000855.s001.doc
https://efashare.b-cdn.net/share/pmc/articles/PMC2964291/bin/pntd.0000855.s002.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC2964291/bin/pntd.0000855.s003.pdf
https://efashare.b-cdn.net/share/pmc/articles/PMC2964291/bin/pntd.0000855.s004.pdf
Authors & Co-Authors
Musa, Ahmed Mudawi
Unknown Affiliation
Younis, Brima Musa
Unknown Affiliation
Fadlalla, Ahmed
Unknown Affiliation
Royce, Catherine
Unknown Affiliation
Balasegaram, Manica
Unknown Affiliation
Wasunna, Monique K.
Unknown Affiliation
Hailu, Asrat
Unknown Affiliation
Edwards, Tansy
Unknown Affiliation
Omollo, Raymond
Unknown Affiliation
Mudawi, Mahmoud M.E.
Unknown Affiliation
K’okwaro, Gilbert O.
Unknown Affiliation
el-Hassan, Ahmed Mohamed A.
Unknown Affiliation
Khalil, Eltahir Awad Gasim
Unknown Affiliation
Statistics
Citations: 93
Authors: 13
Affiliations: 9
Identifiers
Doi:
10.1371/journal.pntd.0000855
Study Locations
Multi-countries
Sudan